EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Methotrexate resistance and its regulatory mechanisms in pediatric tumors and beyond

Jing Nie, Lantian Huang, Yan Shen, Hongai Pan, Siwan Wang, Huawei Zhao, Peng Gao, Jufei Yang, Xiaojun Huang, Su Zeng, Jing Miao

Drug Resistance Updates · 2025-07 · 81 · 101225

DOI: 10.1016/j.drup.2025.101225 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Resistance Updates, 2025-07. Verfasst von Jing Nie und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, Zh…. Hauptthemen laut MEDLINE: Methotrexate, Drug Resistance, Neoplasm, Neoplasms, Antimetabolites, Antineoplastic. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 295 Literaturangaben. Gefördert von: Natural Science Foundation of Zhejiang Province, National Natural Science Foundation of China, China Postdoctoral Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Methotrexate (MTX) is a critical antimetabolite drug in treating various pediatric diseases, including acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL), brain tumors, osteosarcoma, inflammatory myofibroblastic tumor (IMT), juvenile scleroderma (JS), and juvenile idiopathic arthritis (JIA). MTX acts as a folate antagonist by inhibiting dihydrofolate reductase (DHFR), an enzyme essential for the synthesis of tetrahydrofolate. This disruption impairs DNA synthesis, repair, and cellular replication, particularly affecting rapidly dividing cells. Despite its efficacy, MTX resistance poses significant challenges, particularly in pediatric oncology, where it undermines the ability to achieve sustained therapeutic effects, resulting in reduced therapeutic efficacy and poor prognosis. The mechanisms of MTX resistance encompassed reduced enzyme activity pivotal for MTX metabolism, enhanced expression of efflux transporters, genetic variations, and alterations in signaling pathways. Multifaceted strategies have been explored to overcome MTX resistance. Combination therapies with ginger extract, gold nanoparticles, and arsenic trioxide (ATO) have been investigated to augment MTX's cytotoxic effects. Synergies with mTOR inhibitors and MDM2 inhibitors have demonstrated enhanced outcomes in ALL. In JIA, targeting ATP-binding cassette (ABC) transporters and modulating transforming growth factor‑β (TGF-β) signaling pathways have emerged as promising approaches. For osteosarcoma, emphasis on autophagy pathways and non-coding RNAs influencing chemotherapy sensitivity could enhance MTX effectiveness. This review delineates MTX's therapeutic roles, elucidates its resistance mechanisms, and discusses current and potential strategies for managing MTX resistance to bolster treatment effectiveness in pediatric tumors and other diseases. This knowledge base could underpin further research and development of personalized treatments to optimize MTX's clinical benefits.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethotrexateDrug Resistance, NeoplasmNeoplasmsAntimetabolites, AntineoplasticHumansChildSignal TransductionTetrahydrofolate DehydrogenaseFolic Acid AntagonistsAnimals

Stichwörter der Autor:innen

ClinicalDurg resistanceMethotrexatePediatric diseasesTumors

Substanzen

MethotrexateAntimetabolites, AntineoplasticTetrahydrofolate DehydrogenaseFolic Acid Antagonists

Autor:innen und Institutionen

  • Department of Pharmacy, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, Zhejiang 310052, China; Institute of Drug Metabolism and Pharmaceutical…
  • Department of Pharmacy, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, Zhejiang 310052, China.
  • Research Center for Clinical Pharmacy, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
  • Department of Pharmacy, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, Zhejiang 310052, China; Research Center for Clinical Pharmacy, College o…
  • School of Pharmacy, Hangzhou Medical College, Hangzhou, Zhejiang 310059, China.
  • Research Center for Clinical Pharmacy, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; Institute of Drug Metabolism and Pharmaceutical Analysis, College of Pharmaceutical Sciences, Zheji…

Förderung

  • Natural Science Foundation of Zhejiang Province
  • National Natural Science Foundation of China
  • China Postdoctoral Science Foundation
  • Zhejiang Pharmaceutical Association

Zitieren

APA

Nie, J., Huang, L., Shen, Y., Pan, H., Wang, S., Zhao, H., Gao, P., Yang, J., Huang, X., Zeng, S., & Miao, J. (2025). Methotrexate resistance and its regulatory mechanisms in pediatric tumors and beyond. Drug Resistance Updates, 81, 101225. https://doi.org/10.1016/j.drup.2025.101225

Vancouver

Nie J, Huang L, Shen Y, Pan H, Wang S, Zhao H, et al. Methotrexate resistance and its regulatory mechanisms in pediatric tumors and beyond. Drug Resistance Updates. 2025;81:101225. doi:10.1016/j.drup.2025.101225

BibTeX
@article{Nie2025,
  author = {Nie, Jing and Huang, Lantian and Shen, Yan and Pan, Hongai and Wang, Siwan and Zhao, Huawei and Gao, Peng and Yang, Jufei and Huang, Xiaojun and Zeng, Su and Miao, Jing},
  title = {Methotrexate resistance and its regulatory mechanisms in pediatric tumors and beyond},
  journal = {Drug Resistance Updates},
  year = {2025},
  volume = {81},
  pages = {101225},
  doi = {10.1016/j.drup.2025.101225}
}
Kostenlos starten →